David Moffat

1.1k total citations
26 papers, 694 citations indexed

About

David Moffat is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Moffat has authored 26 papers receiving a total of 694 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Moffat's work include Pleural and Pulmonary Diseases (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). David Moffat is often cited by papers focused on Pleural and Pulmonary Diseases (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). David Moffat collaborates with scholars based in Australia, United Kingdom and United States. David Moffat's co-authors include James J. Going, K. H. Overton, Tony Badrick, Bruce Latham, Nigel S. Simpkins, Sonja Klebe, Hubertus Jersmann, Douglas W. Henderson, Annabelle Mahar and Stephen B. Fox and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

David Moffat

26 papers receiving 677 citations

Peers

Countries citing papers authored by David Moffat

Since Specialization

Citations

This map shows the geographic impact of David Moffat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Moffat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Moffat more than expected).

Fields of papers citing papers by David Moffat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Moffat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Moffat. The network helps show where David Moffat may publish in the future.

Co-authorship network of co-authors of David Moffat

This figure shows the co-authorship network connecting the top 25 collaborators of David Moffat. A scholar is included among the top collaborators of David Moffat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Moffat. David Moffat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neoadjuvant immuno-chemo-radiotherapy in operable esophageal and gastroesophageal junction adenocarcinoma with carboplatin, paclitaxel plus radiotherapy and avelumab (anti-PDL1 antibody): Neo-CREATE trial. 2024 ·Journal of Clinical Oncology ·Amitesh Roy, Tim Bright, Nimit Singhal, Matthew Burge, Eva Segelov, Andrew Haydon, Lorraine A. Chantrill, Michael Michael, (unknown), David Moffat, Richard Woodman, Erin L. Symonds, Timothy Price, (unknown), (unknown), Christos S. Karapetis	1
2	Signet-ring cell appearance of atrophic fat cells 2020 ·Forensic Science Medicine and Pathology ·John D. Gilbert, Neil E. I. Langlois, Andrew Ruszkiewicz, David Moffat, (unknown)	2
3	The Incidence of Labelling of Non–Lung Adenocarcinomas With Antibodies Against TTF-1 and Diagnostic Implications 2019 ·Applied immunohistochemistry & molecular morphology ·Sarita Prabhakaran, (unknown), (unknown), David Moffat, (unknown), Douglas W. Henderson, Sonja Klebe	6
4	Accuracy of rapid on-site evaluation of endobronchial ultrasound guided transbronchial needle aspirates by respiratory registrars in training and medical scientists compared to specialist pathologists°™an initial pilot study 2018 ·Journal of Thoracic Disease ·Emily Hopkins, David Moffat, Caroline Smith, (unknown), Ian H. Parkinson, (unknown), (unknown), (unknown), Hubertus Jersmann, Phan Nguyen	10
5	Review of diagnostic error in anatomical pathology and the role and value of second opinions in error prevention 2018 ·Journal of Clinical Pathology ·(unknown), David Moffat, Bruce Latham, Tony Badrick	54
6	Abstract 3877: MPL-5821, a macrophage targeted ESMTM p38 MAPK inhibitor, inhibits the production of TLR agonist induced IL-10 whilst sparing T-cell functionality 2018 ·Cancer Research ·David Moffat, (unknown), A. Marijne Heeren, Tanja D. de Gruijl, Justyna Rzepecka, (unknown), (unknown), (unknown), C. Ian Doris, (unknown), Kathryn Chapman, (unknown), Stephen M. Anderton	1
7	Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non–Small Cell Lung Cancer 2017 ·Clinical Cancer Research ·Wendy A. Cooper, Prudence A. Russell, (unknown), Edwina Duhig, (unknown), Peter J. Jessup, Christine Khoo, Connull Leslie, Annabelle Mahar, David Moffat, (unknown), Céline Faure, (unknown), Amanda Grattan, Stephen B. Fox	100
8	P2.01-047 Intra- and Inter-Observer Reproducibility Study of PD-L1 Biomarker in Non-Small Cell Lung Cancer (NSCLC) - The DREAM STUDY 2017 ·Journal of Thoracic Oncology ·Wendy A. Cooper, Prudence A. Russell, (unknown), (unknown), Edwina Duhig, (unknown), Peter J. Jessup, Christine Khoo, Connull Leslie, Annabelle Mahar, David Moffat, (unknown), Amanda Grattan, (unknown), (unknown), (unknown)	1
9	Cell block samples from endobronchial ultrasound transbronchial needle aspiration provide sufficient material for ancillary testing in lung cancer—a quaternary referral centre experience 2016 ·Journal of Thoracic Disease ·Emily Hopkins, David Moffat, Ian H. Parkinson, Peter Robinson, Hubertus Jersmann, (unknown), (unknown), Kate Francis, Phan Nguyen	28
10	Defective Lung Macrophage Function in Lung Cancer±Chronic Obstructive Pulmonary Disease (COPD/Emphysema)-Mediated by Cancer Cell Production of PGE2? 2013 ·PLoS ONE ·Francis C. Dehle, Violet Mukaro, (unknown), David Moffat, Jessica Ahern, Greg Hodge, Hubertus Jersmann, Paul N. Reynolds, Sandra Hodge	19
11	Increased proteinase inhibitor-9 (PI-9) and reduced granzyme B in lung cancer: Mechanism for immune evasion? 2012 ·Lung Cancer ·(unknown), Violet Mukaro, Greg Hodge, Jessica Ahern, Mark Holmes, (unknown), David Moffat, David Meredith, (unknown), Paul N. Reynolds, Sandra Hodge	42
12	Expression profile of the sphingosine kinase signalling system in the lung of patients with chronic obstructive pulmonary disease 2011 ·Life Sciences ·(unknown), Stuart M. Pitson, Christoph Tabeling, Ian L. Gibbins, David Moffat, Hubertus Jersmann, (unknown), Rainer Haberberger	27
13	Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases 2010 ·Bioorganic & Medicinal Chemistry Letters ·Alastair Donald, Vanessa Clark, Sanjay R. Patel, (unknown), Martin Rowlands, (unknown), Lindsay Stimson, Anthea Hardcastle, Sue Eccles, Deborah A. McNamara, Lindsey Needham, Florence I. Raynaud, Wynne Aherne, David Moffat	5
14	Scalable Synthesis of the VEGF-R2 Kinase Inhibitor JNJ-17029259 Using Ultrasound-Mediated Addition of MeLi−CeCl₃ to a Nitrile 2008 ·The Journal of Organic Chemistry ·Michael Reuman, (unknown), Jeremy Davis, Mark Batchelor, (unknown), David Moffat, Peter J. Connolly, Ronald K. Russell	12
15	Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1) 2007 ·Bioorganic & Medicinal Chemistry Letters ·Shenlin Huang, Ronghua Li, Peter J. Connolly, Stuart L. Emanuel, Angel R. Fuentes‐Pesquera, Mary Adams, Robert H. Gruninger, (unknown), Steven A. Middleton, Jeremy Davis, David Moffat	11
16	4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: Synthesis and biological evaluation 2007 ·Bioorganic & Medicinal Chemistry Letters ·Terry V. Hughes, Stuart L. Emanuel, (unknown), Steven K. Wetter, Peter J. Connolly, Prabha Karnachi, Michael Reuman, (unknown), Angel R. Fuentes‐Pesquera, Robert H. Gruninger, Steven A. Middleton, Ronghui Lin, Jeremy Davis, David Moffat	40
17	The synthesis of bioactive indolocarbazoles related to K-252a 2005 ·Organic & Biomolecular Chemistry ·David Moffat, Christopher J. Nichols, (unknown), Nigel S. Simpkins	11
18	Escaping from Flatland: clinical and biological aspects of human mammary duct anatomy in three dimensions 2004 ·The Journal of Pathology ·James J. Going, David Moffat	112
19	4-Pyridin-5-yl-2-(3,4,5-trimethoxyphenylamino)pyrimidines: Potent and selective inhibitors of ZAP 70 1999 ·Bioorganic & Medicinal Chemistry Letters ·David Moffat, Peter D. Davis, (unknown), Jeremy Davis, Daniel Berg, Mark Batchelor, James M. Johnson, James P. O’Connell, Richard Martin, (unknown), (unknown), (unknown)	14
20	Enantioselective synthesis of optically pure (R)- and (S)-β-lysine via nitrone cycloaddition 1988 ·Journal of the Chemical Society Chemical Communications ·(unknown), David Moffat, K. H. Overton	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact